Daix (France), Long Island City (New York, United States) - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report, with the French 'Autorite? des Marche?s Financiers' (AMF) and its 2021 Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (SEC).

Contact:

Brunswick

Yannick Tetzlaff

Tristan Roquet Montegon

Aude Lepreux

Media

E: inventiva@brunswickgroup.com

T: +33 1 53 96 83 83

(C) 2022 Electronic News Publishing, source ENP Newswire